Most Read Articles
Jairia Dela Cruz, 09 Aug 2019
Uric acid-lowering therapy for gout also confers benefits for hyperlipidaemia, with febuxostat delivering greater reductions in cholesterol and triglyceride concentrations in the blood as compared with allopurinol and benzbromarone, according to a recent study.
Roshini Claire Anthony, 08 Apr 2019

About one-third of individuals who achieved remission of type 2 diabetes (T2D) after losing weight with an intensive weight management programme sustained their remission at 2 years, according to long-term results of the DiRECT* trial.

31 Jul 2019
New drug applications approved by US FDA as of 16 - 31 July 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
12 Aug 2019
Chronic exposure to higher cortisol levels among patients with Turner syndrome (TS) is linked to short stature and greater total cholesterol levels, according to a study. Cortisol exposure also contributes to an increase in cardiovascular disease risk.

Low-intensity resistance training improves muscle strength, glycaemic function in elderly diabetics

10 Sep 2018

Low-intensity resistance training is effective at improving muscle size and strength and glycaemic function in elderly type 2 diabetes patients, a recent study has found.

Nine type 2 diabetes patients (mean age 68.2±9.7 years; 5 males) were recruited and underwent low-intensity resistance training two times a week for 16 weeks. Study outcomes included body weight, fat mass, lean body mass, knee extension and flexion strengths, and changes in fasting HbA1c levels. Wilcoxon signed-rank tests were used to evaluate the changes in outcome variables over time.

The low-intensity resistance training programme demonstrated a significant effect on several measures of body composition. For instance, mean body weight dropped significantly from 65.0±8.7 to 64.1±8.4 kg following the intervention (p=0.0499).

Similarly, significant 16-week reductions were observed for body fat mass (21.2±5.0 to 20.2±5.0 kg; p=0.012) and body fat percentage (32.8±6.8 percent to 31.5±6.6 percent; p=0.012), while significant increases were recorded for total lean body mass (63.6±6.6 percent to 64.7±6.5 percent; p=0.012) and lean body mass of the trunk (30.3±3.5 percent to 31.4±4.1 percent; p=0.017).

Significant improvements in muscle strength were also observed, both for isokinetic knee extension (angular velocity: 60o/s: 72.9±32.1 to 80.4±28.4 N·m; p=0.015; 180o/s: 46.3±17.7 to 52.7±19.6 N·m; p=0.021) and flexion (angular velocity: 60o/s: 42.7±20.7 to 50.9±20.2 N·m; p=0.012; 180o/s: 25.3±12.4 to 36.2±12.3 N·m; p=0.008).

The same was true for maximum leg press strength (62.4±19.9 to 101.2±22.7; p=0.008). In contrast, the 16-week exercise regimen had no significant effect on HbA1c (7.1±0.5 percent to 6.8±0.4 percent; p=0.066) and fasting plasma glucose (124.8±16.5 to 129.6±31.2 mg/dL; p=0.767).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 09 Aug 2019
Uric acid-lowering therapy for gout also confers benefits for hyperlipidaemia, with febuxostat delivering greater reductions in cholesterol and triglyceride concentrations in the blood as compared with allopurinol and benzbromarone, according to a recent study.
Roshini Claire Anthony, 08 Apr 2019

About one-third of individuals who achieved remission of type 2 diabetes (T2D) after losing weight with an intensive weight management programme sustained their remission at 2 years, according to long-term results of the DiRECT* trial.

31 Jul 2019
New drug applications approved by US FDA as of 16 - 31 July 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
12 Aug 2019
Chronic exposure to higher cortisol levels among patients with Turner syndrome (TS) is linked to short stature and greater total cholesterol levels, according to a study. Cortisol exposure also contributes to an increase in cardiovascular disease risk.